摘要
目的 研究和评估安体舒通对实验性大鼠肝纤维化的防治作用 ,探讨其抗肝纤维化作用的可能机制。结果 将雄性Wistar大鼠 80只随机分为正常对照组 (A组 ,16只 ) ,肝纤维化模型组Ⅰ (B组 ,5 4只 ) ,安体舒通治疗组Ⅰ (C组 ,10只 ) ,采用CCl4 复合因素造模 ,治疗组于造模同时予安体舒通每日 10 0mg·kg-1·mL-1灌胃 ,6周末造模成功处死C组大鼠 ,同时随机处死A组及B组大鼠各 8只 ;对B组剩下大鼠行二次随机分组 ,分为模型对照组Ⅱ (D组 ,12只 ) ,安体舒通治疗组Ⅱ (E组 ,10只 ) ,E组于第 7周开始给予安体舒通治疗 ,10周末处死大鼠。检测大鼠肝功能 ,血清透明质酸 (HA) ,层粘蛋白 (LN) ,Ⅲ型前胶原 (PCⅢ ) ,Ⅳ型胶原 (CIV) ;免疫组化法检测肝组织基质金属蛋白酶组织抑制因子 (TIMP -1)的表达。结果 C组与B组比较 ,血清ALT、AST、HA、LN、CIV、PCⅢ均显著降低 (P <0 .0 1) ,TIMP -1活性明显降低 (0 .34± 0 .0 5vs 0 .45± 0 .0 5 ,P <0 .0 1) .E组与D组相较 ,TIMP -1活性亦有明显降低(0 .31± 0 .0 7vs 0 .42± 0 .0 6,P <0 .0 1)。结论 安体舒通对肝纤维化有一定预防作用 ,并可能通过抑制TIMP
Aim To study the effect and mechanism of aldosterone on experimental rat liver fibrosis.Methods Eighty male Wistar rats were randomly divided into three groups:normal control group(A group,16 rats),liver fibrosis model group I (B group,54 rats) and aldosterone group I (C group,10 rats).The rats of group B and C were intraperitoneally injected with CCl 4 to induce liver fibrosis.C group rats were administrated aldosterone from 1st week.All of the C group rats were killed after 6 weeks,8 rats of A group and 8 rats of B group selected randomly were killed in the meantime.The survival rats of B group were randomly divided into two groups:liver fibrosis model groupⅡ(D group,12) and aldosterone groupⅡ(E group,10) which were administrated aldosterone from 7th week.All the rats were killed after 10 weeks.Liver function and serum HA,LN,CIV, PCIII were tested,the expression of TIMP-1 were determined by immunohistochemical staining and analyzed by computer.Results In comparison with group B,the serum level of ALT,AST,HA,LN,CIV, PCIll of group C rats were markedly reduced( P <0.01),the activity of TIMP-1 markedly reduced(0.34±0.05 vs 0.45±0.05, P <0.01).The activity of TIMP-I of group E also markedly reduced in comparison with group D (0.31±0.07 vs 0.42±0.06, P <0.01).Conclusion Aldosterone has obvious effect on liver fibrosis,it might improve the degradation of liver extracellular matrix through inhibiting the activity of TIMP-1.
出处
《胃肠病学和肝病学杂志》
CAS
2003年第1期39-42,共4页
Chinese Journal of Gastroenterology and Hepatology
